Join us on Thursday, March 8, when Rosenman Institute Director Christine Winoto will interview Eric Stone, CEO and co-founder of Velano Vascular. Under Eric’s leadership, Velano’s PIVO needleless blood draw technology won FDA approval; the company raised $17 million this past March; and Velano has just been named to the 2017 Fierce 15 in Medtech.
Mr. Mehrdad Farhangnia serves as the Chief Executive Officer and President at Roxwood Medical, Inc. Mr. Farhangnia joined Roxwood Medical at its formation in January of 2011 and has a successful track record of launching novel medical devices. He has two decades of technical and commercial experience, with prior management roles at Spiracur, Rubicor Medical, FoxHollow Technologies and CardioVention Inc. Prior to his career in medical devices, he spent six years at NASA Ames Research Center, leading collaboration efforts with key aerospace manufacturers and national laboratories. He serves as Director at Roxwood Medical, Inc. He is an inventor of 8 issued patents and has co-authored 10 published articles or conference proceedings. Mr. Farhangnia received his BS and MS degrees in Aerospace Engineering from the University of Colorado.
Amr Salahieh is a seasoned medical device entrepreneur with over 25 years of experience in the medical device industry. Amr is the founder of Shifamed LLC, a Silicon Valley based medical device incubator founded in 2009, from which Legacy Portfolio Companies Maya Medical, Kalila Medical, and Apama Medical have successfully exited and through which three additional companies are currently under incubation. Prior to founding Shifamed, Amr founded Sadra Medical, a percutaneous aortic valve replacement company, which was sold to Boston Scientific in 2011 and co-founded Embolic Protection, Inc. (EPI) which was sold to Boston Scientific in 2001. Amr has extensive R&D management experience stemming from his engineering consulting firm, Sobek Medical LLC which he sold to EPI, and from his work at CardioThoracic Systems and Guidant. Amr is either the inventor or co-inventor on >100 granted and >140 published US patent applications. He holds a B.S. in Biomedical Engineering and a B.S. in Electrical Engineering from Case Western Reserve University.
Dr. Stevens is the CEO of HeartFlow, a company focused on using data from standard CT scans, to create personalized 3D models of the coronary arteries and analyzes the impact that blockages have on blood flow. Trained as a cardiovascular surgeon, He had a distinguished career as an health care professional and entrepreneur. He was the Co-Founder and CTO of Heartport, the Co-Founder and Executive Chairman of Amp Resources, Co-Founder and Chairman and CEO of Sundrop Fuels. He has had extensive experience founding, investing and leading technology focused companies.
Dr. Stevens received his B.S. from the University of Utah and M.D. from the Stanford University School of Medicine. He was an Assistant Professor of Cardiovascular Surgery at Stanford University.
Thomas has 28 years of experience in healthcare with medical devices, biologics, and diagnostics. He has worked with global public companies, private equity, startups, and nonprofits.
He was CEO of Gambro and led the company in the largest private equity transaction in Europe at the time. Previously, Thomas was CEO of HemoCue, which he led to a successful exit. Prior, he was Senior Vice President of Baxter Healthcare / Baxter International and President of Baxter Bioscience. He has also been CEO of Immuno International, a leading global plasma and vaccines company. He was a Managing Director at the World Economic Forum, Davos.
Currently, Thomas is Vice Chairman of Grifols SA, a board member of Sulzer AG and Alkahest, as well as a Healthcare Advisor to Madison Dearborn and Partners.
Thomas is a graduate of Dartmouth College and holds an MBA from IMD in Switzerland. He has a Board of Directors Certification from the UCLA Anderson School of Management. Currently he commutes between the US, Switzerland, and Sweden.
After graduating cum laude from Kent State University with a Bachelors of Business Administration degree and a major in Marketing, Mr. Likens began his professional career with Johnson & Johnson Corporation. He then spent more than twenty years in domestic and international sales, marketing and general management roles at Baxter Healthcare Corporation, culminating in the position of President, Baxter Biotech North America, followed by President of Baxter’s Renal Division in the U.S.
In July of 2006, Mr. Likens became President and CEO and the second employee of Ulthera, Inc., a venture capital-backed start-up company in energy-based aesthetics in Phoenix, AZ. Beginning with European regulatory clearance in late 2008, followed by FDA clearance in September of 2009, Ulthera has realized net revenue growth from $0.5M in ’08 to over $117M in 2014 and been profitable each year since 2012. After filing for an Initial Public Offering in early 2014, Ulthera attracted interest from several larger companies, and in July of that year, was acquired by Merz Pharma GmbH for $600M, an amount representing 6.6x trailing 12-months’ revenue. The Arizona Association for Corporate Growth (ACG) recognized this as Transaction of the Year for 2014.
Phoenix Business Journal honored Mr. Likens in 2012, naming him one of Arizona’s Most Admired CEOs.
In June of 2015, Ernst & Young presented Mr. Likens with the Entrepreneur of the Year for the Mountain Desert Region Award, which recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities.
He has recently been appointed as president and CEO of GT Medical Technologies, seeking to improve the lives of patients with recurrent brain tumors. Over one hundred patients have already been treated with this patent-protected technology and the company is seeking FDA clearance in 2018.
Dr. Omkaram (Om) Nalamasu is senior vice president and chief technology officer (CTO) for Applied Materials. He brings extensive experience and passion to the role of CTO, where he is leading the development of new product pipelines, securing government funding for key strategic projects and building a world-class team to maintain Applied Materials’ technology leadership in the industries it serves and enable growth into new markets. Dr. Nalamasu is also the president of Applied Ventures, LLC, the venture capital fund of Applied Materials, overseeing the financial and strategic investments in early and growth-stage privately held companies.
A world-renowned expert in materials science and technology and one of our industry’s respected forward thinkers, Dr. Nalamasu has championed a renewed focus on the company’s innovation culture through various internal development programs and open innovation methods. He has strengthened Applied Materials’ strategic relationships with universities and research institutes around the world including IIT Bombay.
Dr. Nalamasu joined Applied Materials in 2006, after serving as vice president of research at Rensselaer Polytechnic Institute (RPI). He has held key research and development leadership positions at AT&T Bell Laboratories, Bell Laboratories/Lucent Technologies, and Agere Systems, Inc., and was director of Bell Laboratories’ Nanofabrication Research Laboratory, MEMS and Waveguides Research, and Condensed Matter Physics organizations.
His research interests include nanomanufacturing, nanopatterning, electronic and photonic materials, and lithography, with special emphasis on applying patterning and materials know-how for device fabrication for electronics, photonics and energy applications.
Dr. Nalamasu has made seminal contributions to the fields of optical lithography and polymeric materials science and technology. He has received numerous awards, authored more than 180 papers, review articles and books, and holds more than 35 patents.
Dr. Nalamasu is a member of the board of directors of Semiconductor Research Corporation and The Tech Museum, and serves on the National Academies Panel on Materials Science and Engineering. He sits on several technical advisory boards and university advisory committees, and received his Ph.D. from the University of British Columbia, Vancouver, Canada.
At the Rosenman Institute we’re here to support medtech startups. We connect entrepreneurs to the resources and expertise they need to commercialize their technologies. Helping innovators forge connections is why we’ve brought our legendary symposium back for a fourth year. Join us in San Francisco on June 21 to learn from leaders in the field, meet CEOs of exciting early-stage companies, and get insight on how industry forms strategic partnerships with startups.
During the symposium, we’ll hear lightning presentations from 10 entrepreneurs: the Rosenman Innovators. The Rosenman Innovators are the entrepreneurs selected as finalists for the Medtech Track of the QB3 Life Science Pitch Summits. Rosenman Innovators are eligible to be chosen to receive a wide range of valuable medtech services (valued at $250k) including lab time, prototyping, and design support, plus cash prizes.
Every day, engineers integrate new technology into medical devices. But with the pace of advances in technology and discovery, the potential for devices now far outstrips the state of the art. It is essential for us to reimagine the possibilities. Where better to reimagine devices than the Rosenman Symposium, held at UCSF Mission Bay? Together, we can speed the development of exciting technologies to improve the lives of patients.
Precision medicine is transforming the field of medical devices. How can engineers, investors, clinicians, and medical device professionals anticipate the future? Our June symposium brings Bay Area stakeholders together to share insights and discuss how entrepreneurs can bring new technologies to market for the benefit of patients.